Literature DB >> 2458252

Two distinct genetic loci regulating class II gene expression are defective in human mutant and patient cell lines.

Z Yang1, R S Accolla, D Pious, B J Zegers, J L Strominger.   

Abstract

Heterokaryons were prepared and analyzed shortly after cell fusion using two mutant class-II-negative human B cell lines (RJ 2.2.5 and 6.1.6) and a cell line (TF) from a patient with a class-II-negative Bare Lymphocyte Syndrome. The resulting transient heterokaryons were analyzed by using an anti-HLA-DR monoclonal antibody to assess the cell surface expression of HLA-DR (the major subtype of class II antigens) by immunofluorescence microscopy and by using uniformly 32P-labeled SP6 RNA probes in Northern blots and RNase protection assays to assess mRNA synthesis. We find that class II gene expression in a B cell line from a Bare Lymphocyte Syndrome patient (TF) is rescued by a B cell line which expresses class II antigens indicating that this disease, at least in part, is caused by a defect(s) in a genetic locus encoding a factor(s) necessary for class II gene expression. Secondly, reciprocal genetic complementation was demonstrated in the heterokaryons 6.1.6 x RJ 2.2.5 and TF x RJ 2.2.5 (but not in TF x 6.1.6) by detection of cell surface DR by immunofluorescence microscopy and by a novel class II mRNA typing technique which allows characterization of distinct class II alleles. Thus, the two mutants generated in vitro have defects at two different genetic loci encoding specific regulatory factors necessary for human class II gene expression. One of these mutant cell lines, but not the other, complements the defect in the patient cell line, TF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458252      PMCID: PMC454468          DOI: 10.1002/j.1460-2075.1988.tb03034.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  42 in total

1.  Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.

Authors:  Z Yang; A J Korman; J Cooper; D Pious; R S Accolla; R C Mulligan; J L Strominger
Journal:  Mol Cell Biol       Date:  1987-11       Impact factor: 4.272

Review 2.  Role of MHC gene products in immune regulation.

Authors:  B Benacerraf
Journal:  Science       Date:  1981-06-12       Impact factor: 47.728

3.  Identification of a trans-acting function regulation HLA-DR expression in a DR-negative B cell variant.

Authors:  P Gladstone; D Pious
Journal:  Somatic Cell Genet       Date:  1980-03

4.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

5.  The major histocompatibility complex in man.

Authors:  J Dausset
Journal:  Science       Date:  1981-09-25       Impact factor: 47.728

6.  Cytoplasmic activation of human nuclear genes in stable heterocaryons.

Authors:  H M Blau; C P Chiu; C Webster
Journal:  Cell       Date:  1983-04       Impact factor: 41.582

7.  Isolation of cDNA clones encoding HLA-DR alpha chains.

Authors:  C T Wake; E O Long; M Strubin; N Gross; R Accolla; S Carrel; B Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

Review 8.  Studies in histocompatibility.

Authors:  G D Snell
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

9.  Stable variants affecting B cell alloantigens in human lymphoid cells.

Authors:  D Pious
Journal:  Nature       Date:  1978-02-02       Impact factor: 49.962

10.  Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets.

Authors:  R S Accolla
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

2.  Transcription analysis of class II human leukocyte antigen genes from normal and immunodeficient B lymphocytes, using polymerase chain reaction.

Authors:  M Bull; A van Hoef; J Gorski
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

Review 3.  Transcriptional regulation of HLA class-II genes.

Authors:  B M Peterlin; G Andersson; E Lötscher; S Tsang
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 4.  A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes.

Authors:  R S Accolla; P Dellabona; L Scarpellino; G Carra; S Sartoris
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

5.  Effect of the AIR-1 locus on the activation of an enhancerless HLA-DQA1 promoter.

Authors:  M N Ombra; G Del Pozzo; C Perfetto; A Maffei; J Guardiola
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

Review 6.  Control of transcription at the murine A alpha locus.

Authors:  M Boothby; H C Liou; P W Finn; E Gravallese; L H Glimcher
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 7.  Genetics of HLA class II regulation.

Authors:  C R Hume; J S Lee
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

8.  Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.

Authors:  T Scholl; S K Mahanta; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

9.  Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein.

Authors:  S K Mahanta; T Scholl; F C Yang; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

10.  The MHC class II E beta promoter: a complex arrangement of positive and negative elements determines B cell and interferon-gamma (IFN-gamma) regulated expression.

Authors:  D Thanos; M Gregoriou; D Stravopodis; K Liapaki; T Makatounakis; J Papamatheakis
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.